Currently, an anti-CX3CL1 monoclonal antibody therapy, KANAb001 (E6011), is undergoing phase I and II clinical trial in Japan for RA and Crohn’s disease52. The gene discussed is CX3CL1; the disease is rheumatoid arthritis.